To investigate the roles of MIF and MDK on CAR T-cell modulation, we used CAR T-cells targeting GPC2, which have shown robust safety and efficacy in diverse preclinical models of neuroblastoma and are currently being tested clinically (NCT05650749) [6], [39]. This evidence concerns the gene GPC2 and neuroblastoma.